Clinical PaperHead and Neck OncologyPostoperative adjuvant therapy for patients with loco-regionally advanced oral squamous cell carcinoma who are at high risk of recurrence
Section snippets
Patients
This multicentre retrospective cohort study included all patients with OSCC who also had PCM and/or ENE and who underwent definitive surgery with adjuvant RT or CCRT at six institutions belonging to the Japan Oral Oncology Group between 2002 and 2011. PCM was defined as a microscopically positive or close margin (<5 mm). Treatments with adjuvant RT versus CCRT were based on institutional policies and patient preferences, and therefore varied across the institutions. Patients who had undergone
Patient and treatment characteristics
The demographic characteristics and clinicopathological factors of the study patients are summarized in Table 1. There were more male patients than female patients (male to female ratio 1.7:1), and the median patient age was 64 years (range 25–88 years). The tongue (n = 49, 41.5%) was the most common primary tumour site. Most patients presented with clinical T3–4 stage (n = 79, 66.9%). The clinical N stage was N0–1 in 43 patients (36.4%) and N2–3 in 75 (63.6%). Thirty-eight patients (32.2%) had
Discussion
Postoperative radiation has been widely used to treat patients with advanced HNSCC since 1970, when radiation was shown to be effective against residual tumours post-surgery11. However, the 5-year OS rate was approximately 40%, which was not satisfactory11; hence, additional strategies such as adding chemotherapy to RT have been employed3, 4, 12. Postoperative adjuvant therapy for locally advanced HNSCC is recommended for patients with high risk factors for recurrence such as PCM and/or ENE2, 6
Funding
The study was not funded.
Competing interests
The authors have declared that no competing interests exist.
Ethical approval
Ethical approval was obtained from the Institutional Review Board of Nagasaki University (reference number 18082019). This study conformed to the tenets of the Declaration of Helsinki.
Patient consent
Not required owing to the study’s retrospective nature.
References (21)
- et al.
Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol
(2010) - et al.
Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck
Int J Radiat Oncol Biol Phys
(2012) - et al.
Retrospective study of treatment outcomes after postoperative chemoradiotherapy in Japanese oral squamous cell carcinoma patients with risk factors of recurrence
Oral Surg Oral Med Oral Pathol Oral Radiol
(2017) - et al.
Patterns of failure in patients with locally advanced head and neck cancer treated postoperatively with irradiation or concomitant irradiation with mitomycin C and bleomycin
Int J Radiat Oncol Biol Phys
(2007) - et al.
Feasibility of postoperative concurrent chemoradiotherapy in Japanese patients with oral squamous cell carcinoma showing high-risk factors for recurrence
J Oral Maxillofac Surg Med Pathol
(2015) - et al.
Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer
Int J Radiat Oncol Biol Phys
(2001) - et al.
Adjuvant radiotherapy and survival for patients with node-positive head and neck cancer: an analysis by primary site and nodal stage
Int J Radiat Oncol Biol Phys
(2008) - et al.
Survival outcomes after treatment of cancer of the oral cavity (1985–2015)
Oral Oncol
(2019) Transitions in human development and the global cancer burden
National Comprehensive Cancer Network (NCCN) clinical practice guidelines. Head and neck cancers, version 2.2018
(2019)
Cited by (11)
Photothermal effect of indocyanine green modified scaffold inhibits oral squamous cell carcinoma and promotes wound healing
2022, Biomaterials AdvancesCitation Excerpt :However, the 5-year overall survival rate continues to hover around 30% [2]. In addition, the combined treatment can lead to significant acute and late adverse effects, such as oral mucositis, gastrointestinal reactions, drug resistance and increased incidences of hemotologic adverse events [3,4]. Photothermal therapy (PTT) has emerged as a widely investigated tool against malignant tumors in recent years [5].
TNM 8 staging is a better prognosticator than TNM 7 for patients with locally advanced oral cavity squamous cell carcinoma treated with surgery and post-operative radiotherapy
2021, Radiotherapy and OncologyCitation Excerpt :Interestingly, patients aged less than 60 years and those with less than 10 pack years of smoking were at higher risk. This is in agreement with 2 other studies that have reported patients aged less than 64 years [2] and with less than 20 pack years history of smoking [29] having worse outcomes. These findings suggest a potential distinct subpopulation of OCSCC with perhaps its own biological characteristics.